NO2918604T3 - - Google Patents

Info

Publication number
NO2918604T3
NO2918604T3 NO15154416A NO15154416A NO2918604T3 NO 2918604 T3 NO2918604 T3 NO 2918604T3 NO 15154416 A NO15154416 A NO 15154416A NO 15154416 A NO15154416 A NO 15154416A NO 2918604 T3 NO2918604 T3 NO 2918604T3
Authority
NO
Norway
Application number
NO15154416A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2918604T3 publication Critical patent/NO2918604T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO15154416A 2008-11-07 2009-11-06 NO2918604T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US18329109P 2009-06-02 2009-06-02
US22126909P 2009-06-29 2009-06-29
EP09764710.1A EP2344539B1 (en) 2008-11-07 2009-11-06 Treatment of pediatric acute lymphoblastic leukemia

Publications (1)

Publication Number Publication Date
NO2918604T3 true NO2918604T3 (cg-RX-API-DMAC7.html) 2018-05-19

Family

ID=41796119

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15154416A NO2918604T3 (cg-RX-API-DMAC7.html) 2008-11-07 2009-11-06

Country Status (27)

Country Link
US (2) US20110262440A1 (cg-RX-API-DMAC7.html)
EP (4) EP3330293B1 (cg-RX-API-DMAC7.html)
JP (2) JP5798036B2 (cg-RX-API-DMAC7.html)
KR (1) KR101695329B1 (cg-RX-API-DMAC7.html)
CN (2) CN102209729B (cg-RX-API-DMAC7.html)
AU (1) AU2009313039B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921341A2 (cg-RX-API-DMAC7.html)
CA (1) CA2742242C (cg-RX-API-DMAC7.html)
CY (3) CY1116160T1 (cg-RX-API-DMAC7.html)
DK (3) DK2344539T3 (cg-RX-API-DMAC7.html)
ES (3) ES2662929T3 (cg-RX-API-DMAC7.html)
HK (1) HK1255590B (cg-RX-API-DMAC7.html)
HR (3) HRP20150400T1 (cg-RX-API-DMAC7.html)
HU (3) HUE025452T2 (cg-RX-API-DMAC7.html)
IL (1) IL212651A (cg-RX-API-DMAC7.html)
LT (2) LT3330293T (cg-RX-API-DMAC7.html)
MX (1) MX2011002931A (cg-RX-API-DMAC7.html)
NO (1) NO2918604T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ591312A (cg-RX-API-DMAC7.html)
PL (3) PL2344539T3 (cg-RX-API-DMAC7.html)
PT (3) PT3330293T (cg-RX-API-DMAC7.html)
RS (3) RS59348B1 (cg-RX-API-DMAC7.html)
RU (3) RU2536933C2 (cg-RX-API-DMAC7.html)
SG (1) SG195549A1 (cg-RX-API-DMAC7.html)
SI (3) SI3330293T1 (cg-RX-API-DMAC7.html)
SM (3) SMT201900546T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010052013A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ド読取装置
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP5798036B2 (ja) * 2008-11-07 2015-10-21 アムゲン リサーチ (ミュンヘン) ゲーエムベーハー 小児急性リンパ芽球性白血病の新規治療
EP3517961B1 (en) * 2009-01-09 2020-12-30 Oxford BioMedica (UK) Limited Factors
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
IL282953B2 (en) * 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
CN103131777A (zh) * 2013-02-05 2013-06-05 南京艾迪康医学检验所有限公司 用于检测e2a-pbx融合基因相对表达量的试剂盒
EP3105252B1 (en) 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SI3149480T1 (sl) 2014-05-30 2019-05-31 Amgen Research (Munich) Gmbh Stratifikacija tveganj pri bolnikih z akutno limfoblastno levkemijo prekurzorjev b
US20170252364A1 (en) 2014-07-30 2017-09-07 Mor Research Applications Ltd. Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof
US20170239294A1 (en) * 2014-10-15 2017-08-24 Novartis Ag Compositions and methods for treating b-lymphoid malignancies
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
AU2016215110A1 (en) 2015-02-05 2017-09-21 Stc.Unm Anti-pre-BCR antagonists and methods
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
SI3298042T1 (sl) 2015-05-20 2025-03-31 Amgen Research (Munich) Gmbh Deplecija B celic kot diagnostični marker
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
CN108602889A (zh) * 2015-12-22 2018-09-28 瑞泽恩制药公司 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
EP3430052A2 (en) * 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
WO2017214207A2 (en) * 2016-06-06 2017-12-14 Juno Therapeutics, Inc. Methods for the treatment of b cell malignancies using adoptive cell therapy
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
MA48763A (fr) * 2017-05-05 2020-04-08 Amgen Inc Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
IL327498A (en) 2017-06-02 2026-05-01 Juno Therapeutics Inc Articles of manufacture and methods for treatment using adoptive cell therapy
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR102083481B1 (ko) 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
AU2020214336B2 (en) * 2019-01-30 2026-06-04 The Wistar Institute Of Anatomy And Biology DNA-encoded bispecific T-cell engagers targeting cancer antigens and methods of use in cancer theraputics
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
JP6881658B2 (ja) 2019-07-05 2021-06-02 小野薬品工業株式会社 Pd−1/cd3二重特異性タンパク質による血液がん治療
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023009433A (es) 2021-02-16 2023-11-29 Children´S Health Care D/B/A/ Children´S Minnesota Metodos para el tratamiento de b-all mediante la administracion de un antagonista del complejo pre-bcr.
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
KR20240099263A (ko) 2021-10-15 2024-06-28 암젠 리서치 (뮌헨) 게엠베하 Cd19 결합 t 세포 관여 항체의 피하 투여
US12698512B2 (en) 2023-11-06 2026-08-04 City Of Hope Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
WO2025250648A1 (en) * 2024-05-28 2025-12-04 Ohio State Innovation Foundation Methods and compositions comprising tagless blinatumomab
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4119397A (en) * 1996-08-28 1998-03-19 Viva Diagnostika Diagnostische Produkte Gmbh Novel combination preparations and their use in immunodiagnosis and immunotherapy
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
AU2004242846A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US8076459B2 (en) * 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
US8007796B2 (en) * 2005-12-16 2011-08-30 Micromet Ag Means and methods for the treatment of tumorous diseases
RS53263B (sr) * 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
EP2352763B2 (en) * 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
JP5798036B2 (ja) * 2008-11-07 2015-10-21 アムゲン リサーチ (ミュンヘン) ゲーエムベーハー 小児急性リンパ芽球性白血病の新規治療
RU2538965C2 (ru) * 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
NZ616828A (en) * 2009-01-19 2015-03-27 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8486933B2 (en) * 2009-05-27 2013-07-16 Abbvie Inc. Pyrimidine inhibitors of kinase activity
KR20120085781A (ko) * 2009-09-20 2012-08-01 아보트 러보러터리즈 Bcl-2 단백질 관련 질환을 치료하는데 사용하기 위한 abt-263 결정 형태 및 용매화물
NZ598732A (en) * 2009-10-27 2014-09-26 Amgen Res Munich Gmbh Dosage regimen for administering a cd19xcd3 bispecific antibody

Also Published As

Publication number Publication date
HUE036922T2 (hu) 2018-08-28
PT3330293T (pt) 2019-10-18
CN102209729A (zh) 2011-10-05
RS59348B1 (sr) 2019-10-31
CY1122428T1 (el) 2021-01-27
PL3330293T3 (pl) 2020-02-28
RU2677324C2 (ru) 2019-01-16
HRP20180426T1 (hr) 2018-04-20
RU2018144313A (ru) 2020-06-15
SI3330293T1 (sl) 2019-10-30
DK2918604T3 (en) 2018-03-19
CA2742242A1 (en) 2010-05-14
PT2344539E (pt) 2015-04-01
RU2736802C2 (ru) 2020-11-20
EP2344539A1 (en) 2011-07-20
DK3330293T3 (da) 2019-10-07
HUE025452T2 (en) 2016-05-30
ES2535257T3 (es) 2015-05-07
CN102209729B (zh) 2016-05-25
CY1116160T1 (el) 2017-02-08
PL2918604T3 (pl) 2018-05-30
AU2009313039A1 (en) 2010-05-14
EP3330293B1 (en) 2019-07-24
HUE046222T2 (hu) 2020-02-28
SI2918604T1 (en) 2018-04-30
JP2012508163A (ja) 2012-04-05
US20230235053A1 (en) 2023-07-27
EP2918604B1 (en) 2017-12-20
RS53980B1 (sr) 2015-10-30
NZ591312A (en) 2012-09-28
SMT201800149T1 (it) 2018-05-02
KR101695329B1 (ko) 2017-01-23
WO2010052013A1 (en) 2010-05-14
BRPI0921341A2 (pt) 2016-04-26
ES2662929T3 (es) 2018-04-10
US20110262440A1 (en) 2011-10-27
AU2009313039B2 (en) 2015-06-18
HRP20191715T1 (hr) 2019-12-13
SG195549A1 (en) 2013-12-30
IL212651A (en) 2015-03-31
EP2918604A1 (en) 2015-09-16
JP2015232023A (ja) 2015-12-24
CY1120022T1 (el) 2018-12-12
HK1255590B (en) 2020-07-10
RU2014141180A (ru) 2016-05-10
RS56989B1 (sr) 2018-05-31
LT3330293T (lt) 2019-10-10
HK1215258A1 (en) 2016-08-19
SMT201900546T1 (it) 2019-11-13
MX2011002931A (es) 2011-04-11
RU2014141180A3 (cg-RX-API-DMAC7.html) 2018-06-09
CA2742242C (en) 2023-01-10
CN106390114A (zh) 2017-02-15
HK1158667A1 (en) 2012-07-20
ES2748126T3 (es) 2020-03-13
EP3330293A1 (en) 2018-06-06
RU2018144313A3 (cg-RX-API-DMAC7.html) 2020-06-15
HRP20150400T1 (hr) 2015-05-08
PL2344539T3 (pl) 2015-07-31
LT2918604T (lt) 2018-03-26
DK2344539T3 (en) 2015-05-04
KR20110091669A (ko) 2011-08-12
PT2918604T (pt) 2018-03-02
EP2344539B1 (en) 2015-02-11
RU2536933C2 (ru) 2014-12-27
IL212651A0 (en) 2011-07-31
EP3594237A1 (en) 2020-01-15
SI2344539T1 (sl) 2015-06-30
SMT201500104B (it) 2015-07-09
JP5798036B2 (ja) 2015-10-21
JP6130451B2 (ja) 2017-05-17
RU2011122827A (ru) 2012-12-20

Similar Documents

Publication Publication Date Title
RU2018144313A3 (cg-RX-API-DMAC7.html)
BR112016019572A2 (cg-RX-API-DMAC7.html)
BRPI0909040A2 (cg-RX-API-DMAC7.html)
BRPI0917573A2 (cg-RX-API-DMAC7.html)
BRPI0918697A2 (cg-RX-API-DMAC7.html)
BRPI0920750A2 (cg-RX-API-DMAC7.html)
BRPI0919470A2 (cg-RX-API-DMAC7.html)
BRPI0923734A2 (cg-RX-API-DMAC7.html)
BRPI0922455A2 (cg-RX-API-DMAC7.html)
BRPI0922669A2 (cg-RX-API-DMAC7.html)
BRPI0908285A2 (cg-RX-API-DMAC7.html)
BRPI0910485A2 (cg-RX-API-DMAC7.html)
BRPI0914750A2 (cg-RX-API-DMAC7.html)
BRPI0915616A2 (cg-RX-API-DMAC7.html)
BRPI0908120A2 (cg-RX-API-DMAC7.html)
BRPI0912462A2 (cg-RX-API-DMAC7.html)
BRPI0904541A8 (cg-RX-API-DMAC7.html)
BRPI0920914A2 (cg-RX-API-DMAC7.html)
BRPI0922550A2 (cg-RX-API-DMAC7.html)
BRPI0916284A2 (cg-RX-API-DMAC7.html)
BRPI0913605A2 (cg-RX-API-DMAC7.html)
BRPI0910572A2 (cg-RX-API-DMAC7.html)
BRPI0914820A2 (cg-RX-API-DMAC7.html)
BRPI0919477A2 (cg-RX-API-DMAC7.html)
AR073287B1 (cg-RX-API-DMAC7.html)